SuperworthCytomX Therapeutics EPS CTMX
Diluted earnings per share by quarter and over the last twelve months, from 2014.
- Last 12 months, to Jun 30, 2026
- −$0.45
- Latest quarter, Q2 FY26
- −$0.09
- Fiscal year 2025
- $0.01
- −97% on the year before
CytomX Therapeutics' earnings per share was −$0.45 over the twelve months to Jun 30, 2026, down 180% on a year earlier.
In its latest quarter, Q2 FY26, it was −$0.09.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $0.01 | −97% |
| FY2024 | $0.38 | n/a |
| FY2023 | −$0.02 | n/a |
| FY2022 | −$1.51 | n/a |
| FY2021 | −$1.80 | n/a |
| FY2020 | −$1.40 | n/a |
| FY2019 | −$2.25 | n/a |
| FY2018 | −$2.00 | n/a |
| FY2017 | −$1.18 | n/a |
| FY2016 | −$1.62 | n/a |
| FY2015 | −$29.88 | n/a |
| FY2014 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.09 | n/a | −$0.45 | |
| Q1 FY26 | −$0.10 | −137% | −$0.36 | |
| Q4 FY25 | −$0.17 | −177% | $0.01 | |
| Q3 FY25 | −$0.09 | −229% | $0.40 | |
| Q2 FY25 | $0.00 | n/a | $0.56 | |
| Q1 FY25 | $0.27 | +59% | $0.48 | |
| Q4 FY24 | $0.22 | +2100% | $0.38 | |
| Q3 FY24 | $0.07 | +75% | $0.17 | |
| Q2 FY24 | −$0.08 | n/a | $0.14 | |
| Q1 FY24 | $0.17 | n/a | $0.20 | |
| Q4 FY23 | $0.01 | n/a | −$0.02 | |
| Q3 FY23 | $0.04 | n/a | −$0.16 |
Against its peers
Companies in Drug Manufacturers - General nearest CytomX Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| CTMXCytomX Therapeutics | −$0.45 | −180% a year |
| ARVNArvinas | $0.16 | |
| PBYIPuma Biotechnology | $0.52 | −47% a year |
| IRWDIronwood Pharmaceuticals | $0.77 | |
| ZVRAZevra Therapeutics | $0.93 | |
| CRMDCorMedix | $2.13 | +184% a year |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| ABUSArbutus Biopharma | $0.78 | |
| AMPHAmphastar Pharmaceuticals | $1.70 | −36% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| OMEROmeros | $1.52 | |
| Peer median | $0.97 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on CytomX Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.